Izvorni znanstveni članak
Platelet resistance to anti-aggregating effect of clopidogrel in solid tumor patients
Miroslav Banović
; Department for Transfusional Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Gorana Krajačić-Karas
; Department for Transfusional Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Irena Veliki-Dalić
; Department of Clinical Pathology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Miro Banović
; School of Medicine, University of Rijeka, Rijeka, Croatia
Nikola Lesar
; School of Medicine, University of Rijeka, Rijeka, Croatia
Sažetak
The anti-aggregating effect of clopidogrel (75 mg/day) on platelet function was monitored in 33 solid tumor patients. Clopidogrel irreversibly blocks the platelet P2Y12 receptor and inhibits platelet aggregation induced by adenosine diphosphate (ADP). Whole blood aggregation was measured using a Siemens PFA-100 aggregometer including the Innovance PFA P2Y cartridge. The mean age of patients was 62 ± 13 years. Among them, there were 19 (58%) males and 14 (42%) females. The values of platelet aggregation >106 seconds and <106 seconds showed the anti-aggregating effect of clopidogrel in 22 (67%) and no effect (no response) in 11 (33%) patients, respectively. The average anti aggregating effect of clopidogrel was 219 ± 110 seconds. No differences in platelet aggregation between males and females were observed (p=0.784). The interindividual variation in platelet aggregation was 50%. There was no statistically significant difference between two measurements on 7 samples of the same individuals performed at an interval of a month or more, showing the intraindividual stability of clopidogrel activity on platelet aggregation (p=1.000).
Ključne riječi
tumors; clopidogrel resistance; PFA-100 aggregometer; Innovance PFA P2Y
Hrčak ID:
276091
URI
Datum izdavanja:
30.11.2011.
Posjeta: 397 *